Fintel reports that on August 11, 2023, BTIG maintained coverage of Immunocore Holdings plc - ADR (NASDAQ:IMCR) with a Buy recommendation.
Analyst Price Forecast Suggests 32.21% Upside
As of August 2, 2023, the average one-year price target for Immunocore Holdings plc - ADR is 81.52. The forecasts range from a low of 67.67 to a high of $96.60. The average price target represents an increase of 32.21% from its latest reported closing price of 61.66.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immunocore Holdings plc - ADR is 178MM, a decrease of 2.15%. The projected annual non-GAAP EPS is -0.57.
What is the Fund Sentiment?
There are 214 funds or institutions reporting positions in Immunocore Holdings plc - ADR. This is an increase of 11 owner(s) or 5.42% in the last quarter. Average portfolio weight of all funds dedicated to IMCR is 0.45%, an increase of 2.01%. Total shares owned by institutions increased in the last three months by 8.23% to 35,067K shares. 
The put/call ratio of IMCR is 0.25, indicating a bullish outlook.
What are Other Shareholders Doing?
Rtw Investments holds 5,650K shares representing 11.68% ownership of the company. In it's prior filing, the firm reported owning 5,559K shares, representing an increase of 1.60%. The firm decreased its portfolio allocation in IMCR by 10.19% over the last quarter.
Wellington Management Group Llp holds 3,375K shares representing 6.98% ownership of the company. In it's prior filing, the firm reported owning 2,153K shares, representing an increase of 36.21%. The firm decreased its portfolio allocation in IMCR by 81.06% over the last quarter.
Rock Springs Capital Management holds 3,002K shares representing 6.20% ownership of the company. In it's prior filing, the firm reported owning 3,321K shares, representing a decrease of 10.64%. The firm decreased its portfolio allocation in IMCR by 22.36% over the last quarter.
Baker Bros. Advisors holds 2,521K shares representing 5.21% ownership of the company. No change in the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 2,086K shares representing 4.31% ownership of the company. In it's prior filing, the firm reported owning 1,150K shares, representing an increase of 44.87%. The firm increased its portfolio allocation in IMCR by 68.66% over the last quarter.
Immunocore Holdings Background Information
(This description is provided by the company.)
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.
Additional reading:
- Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements
- MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
- Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by
- 2Q 2023 Financial Results & Business Update Thursday, August 10, 2023 Forward Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Ac
- Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
